Loading clinical trials...
Loading clinical trials...
A Prospective, Observational Study of Canadian Patients Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
Conditions
Locations
29
Canada
Investigational Site Number : 1240019
Calgary, Alberta, Canada
Investigational Site Number : 1240021
Calgary, Alberta, Canada
Investigational Site Number : 1240009
Edmonton, Alberta, Canada
Investigational Site Number : 1240007
Edmonton, Alberta, Canada
Investigational Site Number : 1240028
Nanaimo, British Columbia, Canada
Investigational Site Number : 1240010
Surrey, British Columbia, Canada
Start Date
October 10, 2023
Primary Completion Date
April 10, 2026
Completion Date
April 10, 2026
Last Updated
March 18, 2025
Lead Sponsor
Sanofi
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions